These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Treiber G; Malfertheiner P; Klotz U Expert Opin Pharmacother; 2007 Feb; 8(3):329-50. PubMed ID: 17266468 [TBL] [Abstract][Full Text] [Related]
43. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Tan B; Yang JC; Young CL; Bishu S; Owyang SY; El-Zaatari M; Zhang M; Grasberger H; Qian JM; Kao JY Dig Dis Sci; 2018 Feb; 63(2):437-445. PubMed ID: 29264696 [TBL] [Abstract][Full Text] [Related]
45. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221 [TBL] [Abstract][Full Text] [Related]
46. Effective regimens for the treatment of Helicobacter pylori infection. Morgner A; Labenz J; Miehlke S Expert Opin Investig Drugs; 2006 Sep; 15(9):995-1016. PubMed ID: 16916269 [TBL] [Abstract][Full Text] [Related]
47. In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates. Wang B; Zhao Q; Yin W; Yuan Y; Wang X; Wang YH; Wang H; Ye W; Chen S; Guo HL; Xie Y Swiss Med Wkly; 2018; 148():w14630. PubMed ID: 30044468 [TBL] [Abstract][Full Text] [Related]
48. Antimicrobial activities of ethanol and butanol fractions of white rose petal extract. Park D; Shin K; Choi Y; Guo H; Cha Y; Kim SH; Han NS; Joo SS; Choi JK; Lee YB; Choi EK; Kim JB; Kim YB Regul Toxicol Pharmacol; 2016 Apr; 76():57-62. PubMed ID: 26802535 [TBL] [Abstract][Full Text] [Related]
49. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127 [TBL] [Abstract][Full Text] [Related]
50. Antibiotic treatment strategies for Helicobacter pylori infection. Campo SM; Zullo A; Hassan C; Morini S Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):11-7. PubMed ID: 18221161 [TBL] [Abstract][Full Text] [Related]
51. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109 [TBL] [Abstract][Full Text] [Related]
52. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy. Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684 [TBL] [Abstract][Full Text] [Related]
53. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386 [TBL] [Abstract][Full Text] [Related]